Staging preview: health content pending qualified review
D2C Peptides
Tirzepatide vialResearch vial

Tirzepatide research vial 5 mg to 30 mg

Also searched as: trz glp2

Sold as TRZ GLP2 5mg

$100 In stock

Strength

Research vial. For research use only. Not for human or veterinary use.

Ships from the USA. Shipping details

This research vial holds tirzepatide, a synthetic 39-amino-acid peptide that activates the GIP and GLP-1 receptors.12 The supplier lists the contents as a white freeze-dried (lyophilized) solid and sells it under the name TRZ GLP2.3 Vials come in 5 mg, 20 mg, 30 mg sizes, labeled for research use only, and bacteriostatic water is sold separately.3

Specifications

Sequence (one-letter code)YXEGTFTSDY SIXLDKIAQK AFVQWLIAGG PSSGAPPPS (39 residues; X = non-standard residue; a C20 fatty diacid is attached through a linker to lysine 20)41
Molecular formulaC225H348N48O685
Molar mass4813 g/mol (PubChem computed value)5
CAS number2023788-19-22
PubChem CID1565883245
FormWhite lyophilized (freeze-dried) solid, per the supplier3
Vial contentsTirzepatide, by vial size: 5 mg, 20 mg, 30 mg. Bacteriostatic water is not included.3
Strengths5 mg, 20 mg, 30 mg
Ships fromUSA
CategoryWeight Loss Peptides
StoragePeptide makers advise keeping freeze-dried peptides tightly closed and frozen (about -20 °C, away from bright light) for longer storage, and Bachem allows a 4 °C refrigerator for short-term use.1415 No stability data for this vial were reviewed, and research-labeled tirzepatide has no FDA-reviewed storage directions.67

Supplies for Tirzepatide

Bulk and wholesale orders

Labs ordering tirzepatide wholesale, or looking for one tirzepatide supplier for repeat orders, can apply for a wholesale account, with terms confirmed on application. Our guide to bulk tirzepatide research vials covers the per-milligram math.

Wholesale detailsApply for a wholesale account

Questions about Tirzepatide

About Tirzepatide

Tirzepatide is a synthetic peptide developed under the research code LY3298176.10 It is a 39-amino-acid linear peptide joined through a linker to a C20 fatty diacid at lysine 20.1 FDA's pharmacologic class terms describe it as both a GIP receptor agonist and a GLP-1 receptor agonist.2 The supplier's name for this vial, TRZ GLP2, does not describe its activity: those class terms name the GIP and GLP-1 receptors, not a GLP-2 receptor.2

Human evidence comes from randomized trials of a once-weekly injection, such as a 40-week trial in 478 adults with type 2 diabetes and a 72-week trial in 2,539 adults with obesity, or overweight with a weight-related complication, who did not have diabetes.1112 The tirzepatide for sale here is a research-labeled vial of freeze-dried peptide,3 not an FDA-approved drug.7 Before you buy tirzepatide for a study, read What is Tirzepatide? for the trial results, side effects and regulatory picture. Related vials are in Weight Loss Peptides and on the full peptides shop page.

Research highlights

  • Receptor binding (cell studies, 2018): tirzepatide bound the GIP receptor about as strongly as natural GIP, and the GLP-1 receptor about 5 times more weakly than natural GLP-1.1
  • Glucagon receptor (cell studies, 2018): it had minimal activity at the closely related glucagon receptor.1
  • Receptor balance (2020 analysis): an estimate of receptor occupancy at clinically effective doses found greater engagement of the GIP receptor than the GLP-1 receptor.10
  • Signaling (cell studies, 2020): it mimicked natural GIP at the GIP receptor, but at the GLP-1 receptor it favored cAMP signaling over beta-arrestin recruitment.10
  • Liver (NIH LiverTox review): it has been linked to few cases of raised liver enzymes during therapy and to rare cases of clinically apparent liver injury.13

FDA calls research-labeled GLP-1 products sold to consumers of unknown quality and possibly harmful, so published findings on tirzepatide cannot be assumed to apply to any research vial.7

Regulatory status

FDA has warned companies that sold unapproved tirzepatide falsely labeled "for research purposes" or "not for human consumption", and says such products have reached consumers with dosing instructions.7 This vial carries a research-use label and is not an FDA-approved drug.37 FDA warning letters to three online sellers, dated December 2024, March 2026 and August 2026, called their research-labeled tirzepatide an unapproved new drug.869 In each letter, FDA said that despite the research-use labels, evidence from the seller's website showed the products were intended as drugs for human use.869

Handling and storage

The vial holds freeze-dried tirzepatide, and bacteriostatic water is sold separately.3 No FDA-reviewed directions exist for mixing or storing research-labeled tirzepatide.67 Labs that buy tirzepatide online from D2C Peptides can find the concentration math, the supplies list and what is and is not known about storage in How to reconstitute Tirzepatide. The reconstitution calculator checks the arithmetic for any vial size.

Frequently asked questions

What sizes does the tirzepatide vial come in?

The vial is listed in 5 mg, 20 mg, 30 mg sizes, from $100, and the strength selector shows current stock. The supplier describes the contents as a white freeze-dried solid and does not state excipients or salt form.3 Tirzepatide price and cost explains how vial size changes the cost per milligram.

What supplies are used with this vial?

The peptide comes dry, and the supplier states that bacteriostatic water is not included.3 D2C Peptides lists five supplies for this vial, sold separately: bacteriostatic water, a 3 mL Luer-Lok syringe, an 18G 1-inch needle, insulin syringes and alcohol swabs. Concentration math for a dry vial is in How to reconstitute Tirzepatide.

How is the vial shipped, and how should it be stored on arrival?

Shipping options and timing are on the shipping page, and the return policy is on the returns page. Bachem, a peptide maker, says freeze-dried peptides may be shipped at room temperature and kept in a 4 °C refrigerator for short-term use; for longer storage, makers advise a tightly closed vial in a freezer at about -20 °C, away from bright light.1415 No stability data for this vial were reviewed, and research-labeled tirzepatide has no FDA-reviewed storage directions.67 More is in How to store peptides.

Does the vial come with a certificate of analysis?

Testing documents, when published, appear on the lab results page, and this product page makes no purity or testing claim of its own. A certificate of analysis is a lab report on one production lot, usually covering identity and purity. Questions about a specific order go through the contact page.

Is this tirzepatide approved for human use?

No. The supplier labels its products for research purposes only, not for human consumption.3 FDA has called tirzepatide sold under research-use labels an unapproved drug, and no dose for people is established for it.76 In warning letters to three other sellers, FDA said that despite such labels, the sellers' websites showed the products were intended as drugs for human use.869

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (Coskun et al.). Molecular Metabolism, 2018.
  2. Tirzepatide, CID 156588324: Names and Identifiers (FDA Pharm Classes description). PubChem, NIH National Library of Medicine, 2026.
  3. Supplier product specification.
  4. KEGG DRUG D11360: Tirzepatide. KEGG, Kanehisa Laboratories, 2026.
  5. Tirzepatide, CID 156588324: computed properties (PUG REST). PubChem, NIH National Library of Medicine, 2026.
  6. FDA Warning Letter: Gram Peptides (MARCS-CMS 721806), March 31, 2026. U.S. Food and Drug Administration, CDER, 2026.
  7. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026): adverse event reports. U.S. Food and Drug Administration, 2026.
  8. FDA Warning Letter: Summit Research Peptides (MARCS-CMS 695607), December 10, 2024. U.S. Food and Drug Administration, CDER, 2024.
  9. FDA Warning Letter: Royal Peptides LLC (MARCS-CMS 734884), August 24, 2026. U.S. Food and Drug Administration, CDER, 2026.
  10. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (Willard et al.), PubMed record PMID 32730231. JCI Insight (via NLM PubMed E-utilities), 2020.
  11. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1), PMID 34186022. The Lancet (via NLM PubMed E-utilities), 2021.
  12. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), PMID 35658024: methods. New England Journal of Medicine (via NLM PubMed E-utilities), 2022.
  13. Tirzepatide, CID 156588324: LiverTox Summary annotation. PubChem, NIH National Library of Medicine (source: LiverTox, NIDDK), 2026.
  14. Handling and Storage Guidelines for Peptides (Peptide Guide, chapter 8). Bachem.
  15. Peptide Storage and Handling Guidelines. GenScript.
Shop all peptidesMore weight loss peptides